Tirzepatide
BRANDS Mounjaro · Zepbound
Last reviewed 2026-10-30
Our read Opinion
An approved metabolic medicine with substantial randomized-trial evidence. Compounded products remain unapproved and subject to statutory restrictions.
- Type
- FDA-approved
- Regulatory status
- FDA-approved (Mounjaro, Zepbound)
- Compounding status
- Approved product (not applicable)
- FDA-approved indications
- Mounjaro: glycemic control in type 2 diabetes (adults in cited label). Zepbound: long-term weight management in eligible adults; moderate-to-severe obstructive sleep apnea in adults with obesity.
- Evidence level
- Human RCTs (approved use)
- Routes studied
- Injection
- WADA
- Not prohibited
- Developer
- Eli Lilly and Company
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Reported to produce substantial weight reduction in phase 3 trials
Dual GIP and GLP-1 receptor agonist that improves glucose-dependent insulin secretion and reduces food intake.
FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obesity-associated obstructive sleep apnea in specified populations. Approved status does not authorize routine compounded copies.
Statuses change; check the linked primary source.
Momentum Opinion
Rising
1 news items in last 30 days
The clinical evidence is substantial, but benefits depend on indication and patient selection. Marketing should not obscure tolerability, contraindications or the distinction between approved and compounded products.
NEJM
A secondary analysis reports outcomes in adults with obesity and sleep apnea.
Lose fat on a GLP-1 while holding on to muscle.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.